Pegylated liposomal doxorubicin does not affect cardiac function in patients treated for gynecologic malignancies
Risk of cardiac toxicity from administration of PLD for patients undergoing treatment for gynecologic cancers appears to be low. Selective screening of cardiac function should be employed for these patients.
Authors
- Miranda Benfield
- Erin K. Crane (ORCID: https://orcid.org/0000-0001-6896-6141)
- R. Wendel Naumann (ORCID: https://orcid.org/0000-0002-2739-165X)
- Brittany Lees
- Allison Puechl (ORCID: https://orcid.org/0000-0003-0761-7727)
- Khrystyna Levytska (ORCID: https://orcid.org/0000-0003-4214-6799)
- Yovanni Casablanca (ORCID: https://orcid.org/0000-0003-1476-1508)
- Jubilee Brown (ORCID: https://orcid.org/0000-0002-2555-5518)
Institutions
- Cedars-Sinai Medical Center (US)
- Levine Cancer Institute (US)
Publication Details
- Journal
- Gynecologic Oncology Reports
- Published
- 2025-03-17
- DOI
- https://doi.org/10.1016/j.gore.2025.101727
- Citations
- 2
- Primary Topic
- Chemotherapy-induced cardiotoxicity and mitigation
- Type
- article
- Field-Weighted Citation Impact
- 2.78